TABLE 6.
Brucella IgM and IgG flow assay results and comparison with standard serological assays during follow-up of treated patients
| Period (mo) (n)a | % Positive (95% CI) in the indicated assay
|
|||||
|---|---|---|---|---|---|---|
| IgM flow, ≥1+ | IgG flow, ≥1+ | SAT, ≥1:320 | SAT, ≥1:160 | SAT-DTT, ≥4-fold titer reduction | Coombs, ≥1:320 | |
| Initial sample (26) | 62 (41-79) | 69 (48-85) | 54 (34-73) | 73 (52-88) | 54 (34-73) | 100 (84-100) |
| 0-1 (16) | 75 (44-87) | 81 (50-92) | 44 (21-69) | 81 (50-92) | 68 (39-85) | 88 (62-98) |
| 1-2 (23) | 61 (39-80) | 87 (61-94) | 26 (11-49) | 48 (27-69) | 35 (17-57) | 91 (71-99) |
| 2-3 (16) | 31 (12-59) | 69 (42-88) | 19 (5-46) | 31 (12-89) | 31 (12-59) | 88 (58-96) |
| 3-6 (18) | 22 (7-48) | 61 (36-82) | 6 (0-29) | 22 (7-48) | 18 (4-42) | 83 (58-96) |
| >6 (21) | 19 (6-43) | 38 (19-61) | 0 (0-20) | 10 (2-32) | 19 (6-43) | 57 (34-77) |
a
n, number of samples.